Pharmacokinetic/Pharmacodynamic Profile of Posaconazole

@article{Li2010PharmacokineticPharmacodynamicPO,
  title={Pharmacokinetic/Pharmacodynamic Profile of Posaconazole},
  author={Yanjun Li and Ursula Theuretzbacher and Cornelius J. Clancy and M. Hong Nguyen and Hartmut Derendorf},
  journal={Clinical Pharmacokinetics},
  year={2010},
  volume={49},
  pages={379-396}
}
Posaconazole is a recently approved lipophilic triazole antifungal agent that exhibits potent and broad-spectrum antifungal activity in vitro and in vivo against most Candida spp., Cryptococcus neoformans, Aspergillus spp., many Zygomycetes, endemic fungi and dermatophytes. It has been documented that posaconazole has potency and spectrum of activity similar to those of itraconazole and superior to those of fluconazole against clinically important isolates of Candida spp., C. neoformans and… Expand
The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies
TLDR
For today posaconazole included in all relevant clinical recommendations with high levels of evidence, including prophylaxis of invasive mycoses and therapy of their refractory forms, while the authors agree that for the oral therapy a preference should be given to the tablet formulation of posaconzole. Expand
Posaconazole: when and how? The clinician’s view
TLDR
Results of Phase III clinical trials and case/series reports indicate that posaconazole is effective in treating oesophageal candidiasis, including azole‐refractory disease, and other IFI refractory to standard antifungal therapies. Expand
Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections
TLDR
The posaconazole tablet achieves higher and more consistent mean plasma concentrations than the suspension and, therefore, it is the preferred option to optimize efficacy in the prophylaxis or treatment of invasive fungal disease. Expand
Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring
TLDR
In patients with subtherapeutic posaconazole concentrations, increased dose frequency, administration with high-fat meals, and withdrawal of interacting medications from therapy are useful strategies to improve systemic absorption. Expand
In vitro and in vivo evaluation of a posaconazole-sulfobutyl ether-β-cyclodextrin inclusion complex.
TLDR
A sulfobutyl ether-β-cyclodextrin compound was used to prepare an intramuscular injection to improve the bioavailability of posaconazole, and the extracorporeal dissolution rate of posconazole was markedly improved by this inclusion complex. Expand
Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area
TLDR
Posaconazole is a promising antifungal agent to be used prophylactically in hematologic patients aged 13 years or younger, and Administering posaconazoles oral suspension in a dosage of 120 mg/m2 tid results in adequate posaconzole plasma exposure, without significant adverse events. Expand
Bioavailability of voriconazole in hospitalised patients.
TLDR
The findings suggest that factors other than bioavailability may cause the observed difference in voriconazole trough concentrations between oral and i.v. administration in the earlier studies and stress the need for an antimicrobial stewardship team to guide voriconsazole dosing. Expand
New generation azole antifungals in clinical investigation
  • C. Girmenia
  • Medicine
  • Expert opinion on investigational drugs
  • 2009
TLDR
Literature evidences strongly support the use of therapeutic drug monitoring for these triazoles, in particular voriconazole and posaconazole, which may be crucial for the proper management of severe invasive fungal infections. Expand
Pharmacology and clinical use of voriconazole
TLDR
This review discusses the mechanism of action, the pharmacodynamics and pharmacokinetics and the most common mechanisms of resistance to this agent, an extended-spectrum triazole developed specifically to target Aspergillus spp. Expand
Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity
TLDR
Liposomal VCZ presents an alternative therapeutic platform, leading to a safe and effective treatment against systemic fungal infections, and PKs and biodistribution of VCZ modified by encapsulation into liposomes resulted in improved antifungal activity, due to increased specificity and tissue penetration. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 185 REFERENCES
Posaconazole (Noxafil): A New Triazole Antifungal Agent
  • N. Greer
  • Biology, Medicine
  • Proceedings
  • 2007
TLDR
The most common adverse effects reported with posaconazole therapy were fever, diarrhea, nausea, vomiting, and headache, and these laboratory values should be monitored during treatment with posconazole. Expand
Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
  • V. Nagappan, S. Deresinski
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
TLDR
The major roles for posaconazole in clinical practice are as prophylaxis for neutropenic patients with significant risk of infection with filamentous fungi and as therapy for zygomycoses, and assessment of its overall place in antifungal therapy awaits the availability of further clinical experience. Expand
Posaconazole: clinical pharmacology and potential for management of fungal infections
TLDR
Posaconazole has demonstrated strong antifungal efficacy in Phase II and III clinical trials in immunocompromised patients with oropharyngeal and esophageal candidiasis and it is currently under regulatory review in the USA and Europe for the treatment of refractory invasive fungal infections. Expand
Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis
TLDR
Investigations demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic-pharmacodynamic (PK-PD) parameter associated with treatment efficacy and was predictive of treatment success in both experimental models and clinical trials. Expand
Posaconazole: a broad-spectrum triazole antifungal.
TLDR
In-vitro and in-vivo studies showed that posaconazole has broad-spectrum activity against most Candida species, Cryptococcus neoformans, Aspergillus species, Fusarium species, zygomycetes, and endemic fungi. Expand
Pharmacokinetics/pharmacodynamics of echinocandins
  • U. Theuretzbacher
  • Biology, Medicine
  • European Journal of Clinical Microbiology and Infectious Diseases
  • 2004
TLDR
Increased incorporation of these principles in experimental and clinical studies is an important objective that will benefit the treatment and prophylaxis of life-threatening invasive fungal infections in immunocompromised patients. Expand
Pharmacokinetic/Pharmacodynamic Profile of Voriconazole
TLDR
Voriconazole is the first available second-generation triazole with potent activity against a broad spectrum of clinically significant fungal pathogens, including Aspergillus, Candida, Cryptococcus neoformans, and some less common moulds, and the potential for drug interactions is considerable. Expand
In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.
TLDR
Both posaconazole and ravuconazole showed similar broad-spectrum activity against dermatophyte, yeast and non-dermatophyte species and were compared with three well-established antifungal agents against 184 clinical isolates. Expand
In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model
TLDR
Investigations demonstrated that the ratio of the area under the concentration-time curve from 0 to 24 h to the MIC (24-h AUC/MIC ratio) is the critical pharmacokinetic/pharmacodynamic (PK/PD) parameter associated with treatment efficacy. Expand
Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects
TLDR
Observations suggest that oxidative (phase 1) metabolism by cytochrome P450 isoforms represents only a minor route of elimination for posaconazole, and therefore cyto Chrome P450-mediated drug interactions should have a limited potential to impact posaconzole pharmacokinetics. Expand
...
1
2
3
4
5
...